T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$7.49B |
| 2 |
Micron Technology
MU
|
+$6.62B |
| 3 |
Lam Research
LRCX
|
+$3.45B |
| 4 |
Applied Materials
AMAT
|
+$3.03B |
| 5 |
Advanced Micro Devices
AMD
|
+$2.91B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$12.1B |
| 2 |
Apple
AAPL
|
+$11.6B |
| 3 |
Amazon
AMZN
|
+$3.54B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.07B |
| 5 |
Keysight
KEYS
|
+$1.82B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.73% |
| 2 | Healthcare | 11.3% |
| 3 | Financials | 10.32% |
| 4 | Communication Services | 9.66% |
| 5 | Industrials | 9.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2426
Backblaze
BLZE
$816M
| $775K | ﹤0.01% |
48,804
+4,745
| +11% | +$32.8K |
|
2427
Savara
SVRA
$1.03B
| $775K | ﹤0.01% |
125,676
+24,204
| +24% | +$130K |
|
2428
Vor Biopharma
VOR
$1.1B
| $770K | ﹤0.01% |
+41,815
| New | +$633K |
|
2429
Kura Oncology
KURA
$957M
| $768K | ﹤0.01% |
69,962
+11,868
| +20% | +$112K |
|
|
QNT
2430
Quantinuum Inc
QNT
$1.94B
| $767K | ﹤0.01% |
+9,383
| New | +$603K |
|
2431
AMC Global Media
AMCX
$502M
| $766K | ﹤0.01% |
76,741
+12,811
| +20% | +$114K |
|
2432
Excelerate Energy
EE
$1.04B
| $765K | ﹤0.01% |
20,123
+2,093
| +12% | +$72.1K |
|
|
NXH
2433
Neighborhood Intelligence Inc
NXH
$317M
| $763K | ﹤0.01% |
131,640
+48,928
| +59% | +$268K |
|
|
AGNT
2434
AGNT Inc
AGNT
$607M
| $757K | ﹤0.01% |
139,764
+25,105
| +22% | +$138K |
|
2435
Regenxbio
RGNX
$488M
| $757K | ﹤0.01% |
63,126
+11,997
| +23% | +$99.6K |
|
2436
Forum Energy Technologies
FET
$950M
| $752K | ﹤0.01% |
14,955
+1,748
| +13% | +$97.5K |
|
2437
Sprout Social
SPT
$578M
| $751K | ﹤0.01% |
99,389
+22,361
| +29% | +$146K |
|
|
REFI
2438
Chicago Atlantic Real Estate Finance
REFI
$273M
| $745K | ﹤0.01% |
69,485
+12,524
| +22% | +$144K |
|
2439
Inhibrx
INBX
$1.47B
| $741K | ﹤0.01% |
7,812
+800
| +11% | +$80.2K |
|
|
BKV
2440
BKV Corp
BKV
$2.39B
| $740K | ﹤0.01% |
27,013
+8,938
| +49% | +$246K |
|
2441
Annexon
ANNX
$690M
| $738K | ﹤0.01% |
129,243
-299,477
| -70% | -$1.66M |
|
2442
Phibro Animal Health
PAHC
$1.4B
| $738K | ﹤0.01% |
23,494
+2,635
| +13% | +$111K |
|
|
XRN
2443
Chiron Real Estate Inc
XRN
$475M
| $734K | ﹤0.01% |
19,547
+1,701
| +10% | +$60.3K |
|
2444
FLEX LNG
FLNG
$1.67B
| $732K | ﹤0.01% |
26,085
+3,670
| +16% | +$113K |
|
2445
4D Molecular Therapeutics
FDMT
$799M
| $730K | ﹤0.01% |
54,869
+12,422
| +29% | +$121K |
|
2446
State Street Technology Select Sector SPDR ETF
XLK
$128B
| $729K | ﹤0.01% |
3,824
| – | – |
|
|
OSG
2447
Octave Specialty Group
OSG
$189M
| $728K | ﹤0.01% |
116,612
+14,647
| +14% | +$76.3K |
|
2448
Amerant Bancorp
AMTB
$1.16B
| $728K | ﹤0.01% |
28,508
+734
| +3% | +$17.1K |
|
2449
C4 Therapeutics
CCCC
$367M
| $728K | ﹤0.01% |
155,881
+84,335
| +118% | +$288K |
|
|
GOOD
2450
Gladstone Commercial Corp
GOOD
$605M
| $727K | ﹤0.01% |
59,026
+8,006
| +16% | +$99.7K |
|
Similar funds
T. Rowe Price Associates's Q2 2026 Portfolio in Review
As of Q2 2026, T. Rowe Price Associates held 3,356 positions worth $999B, up 16% from $865B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2026 filing shows 224 new, 2,237 increased, 645 reduced and 116 closed positions. Its largest new stake was SpaceX: 10,709,016 shares worth $1.83B. The largest sale was Microsoft, an estimated $12.1B.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q2 2026 buy was SpaceX: 10,709,016 shares worth $1.83B.
- T. Rowe Price Associates added most to Alphabet (Google) Class A in Q2 2026, an estimated $7.49B increase.
- T. Rowe Price Associates's biggest Q2 2026 reduction was Microsoft, cutting an estimated $12.1B.
- T. Rowe Price Associates fully exited Sibanye-Stillwater in Q2 2026, selling an estimated $40.4M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $999B portfolio in Q2 2026.
- T. Rowe Price Associates opened 224 new positions and closed 116 in Q2 2026.
- T. Rowe Price Associates's portfolio value rose 16% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.